Our study demonstrates for the first time that PTA ameliorates cardiac remodeling and dysfunction in mice with pathological cardiac hypertrophy by suppressing oxidative stress and cardiomyocyte pyroptosis through activating of the Nrf2 signaling pathway, highlighting additional therapeutic option for clinical prevention and treatment of HF patients. This evidence concerns the gene NFE2L2 and cardiac hypertrophy.